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INTRODUCTION 
Anticoagulant medications such as aspirin, warfarin, 
clopidogrel, ticlopidine, prasugrel, dipyridamole, 
cilostazol and dabigatran are used for the prevention 
of atherothrombotic events in patients with a history 
of myocardial infarction, ischaemic stroke, acute 
coronary syndrome or peripheral arterial diseases, 
particularly in those who have undergone stent 
placement following percutaneous coronary 
intervention, coronary artery bypass surgery, or 
prosthetic valve replantation.1 All anticoagulant 
medications affect clotting by irreversibly inhibiting 
platelet aggregation within one (e.g., aspirin, 
prasugrel) to two (e.g., clopidogrel) hours of 
administration, with the inhibition lasting for the 
entire lifespan of the platelets (i.e., 7-10 days).2 This 
anticoagulant effect can only be overcome by the 
production of new platelets.3 Complete recovery of 
platelet function occurs by day four in 80% of the 
cases.4 In contrast, non-steroidal anti-inflammatory 
drugs (NSAIDs) other than aspirin (e.g., ibuprofen, 
diclofenac, piroxicam etc.) have a reversible effect on 
platelet aggregation, and normal platelet function is 
restored once the drug is cleared from the 
circulatory system.3 Thus, NSAIDs other than aspirin 
are not used clinically for anticoagulant therapy.  
 
All patients receiving anticoagulant therapy are 
likely to possess drug-induced altered platelet 
function.5 Low-dose aspirin can double the baseline 
bleeding time while clopidogrel may prolong it by 1.5  
 
to 3 times; however, the resulting bleeding time may 
still be within the normal limits.3,6 In a placebo-
controlled study, designed to assess the effect of 
cessation of low-dose aspirin on bleeding time in 
healthy volunteers after 14 days of treatment, the 
mean prolongation of bleeding time after 24 hours 
of cessation of treatment was 22 secs, 105 secs, and 
211 secs, respectively, for patients on placebo, 75 mg 
aspirin, and 300 mg aspirin (normal range of 
bleeding time specified in the study: 120-600 secs).7 
Bleeding times in all the subjects returned to 
baseline values by the sixth day. Although the effect 
on primary hemostasis is marginal when 
anticoagulants are used as monotherapy,8 there is 
likely to be an increased bleeding tendency if they 
are used as a combination therapy.6  
 
Risk Associated with Perioperative 
Anticoagulant Discontinuation 
Because of concerns about excessive periprocedural 
and postprocedural bleeding, many clinicians 
recommend reducing the dosage or completely 
stopping anticoagulant medications prior to carrying 
out periodontal surgical therapy and even 
subgingival scaling and root surface debridement. 
However, evidence from the extant literature and 
current consensus indicate that anticoagulant drug 
regimens should not be altered prior to dental 
surgical procedures.9-13 Stroke and myocardial 
infarction have been increasingly associated with  
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Periodontists are encountering increasing number of cases in their practices where patients present with cardiovascular diseases. Patients 
with a history of myocardial infarction, ischaemic stroke, acute coronary syndrome or peripheral vascular disease are prescribed 
anticoagulant medications by cardiologists, such as aspirin, warfarin, clopidogrel, ticlopidine, prasugrel, dipyridamole, cilostazol or 
dabigatran- either as monotherapy or dual therapy, for prevention of further thromboembolic events during lifetime. As because these 
agents act by inhibiting platelet aggregation, they tend to prolong bleeding time. Concerns regarding excessive periprocedural bleeding in 
patients receiving such drugs have led to some clinicians recommending periprocedural discontinuation of anticoagulant therapy. However, 
several studies, including systematic reviews and meta-analyses, have proved that there is no significantly increased risk of bleeding 
associated with continuing anticoagulant therapy when compared with discontinuation or modification of the anticoagulant regimen. In 
fact, without the anticoagulant medication, these patients have been found to be at increased risk of thromboembolic events with 
potentially serious consequences. The accepted recommendation, therefore, is that the anticoagulant drug regimens should not be altered or 
discontinued prior to periodontal treatment procedures, as the risks associated with such discontinuation far outweigh the consequences of 
prolonged bleeding, which can be well controlled with local measures. 
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perioperative interruption or cessation of  
anticoagulant drug regimen. In a prospective cohort 
study of 1358 hospitalized patients with acute 
coronary syndrome, 6% (n=73) had recently (within 
12 days prior to admission) discontinued oral 
anticoagulants for planned surgery.14 Many of these 
patients had suffered catastrophic outcomes during 
the 30-day follow-up period with a two-fold increase 
in mortality rate and major bleeding episodes when 
compared with those who did not discontinue. In a 
similar study of 1236 patients admitted to the 
hospital for acute coronary syndrome, it was found 
that 4% of the patients (n=51) had stopped aspirin in 
the month prior to admission.4 However, 13.3% of all 
recurrences were from this group, with the mean (± 
SD) delay between aspirin withdrawal and the acute 
coronary event being 10 (±1.9) days (range: 4-17 
days). Of these, 13 patients (25.5%) discontinued 
aspirin prior to receiving periodontal treatment and 
dental extractions. In a retrospective study involving 
475 hospitalized patients with myocardial infarction, 
one patient, who had been stable and symptom free 
on aspirin for 10 years, discontinued aspirin therapy 
prior to a planned periodontal surgical procedure 
and suffered a myocardial infarction 10 days after 
discontinuing aspirin therapy.15  
 
A meta-analysis of studies reporting on the 
cardiovascular risks associated with the continued 
use of low-dose aspirin versus its perioperative 
discontinuation, found that out of 93 patients 
presenting with acute vascular events after cessation 
of low-dose aspirin, 14 (15.1%) had discontinued due 
to planned dental surgery.16 The time interval 
between aspirin discontinuation and acute vascular 
event was 8.5 (±3.6) days for acute coronary 
syndrome, 14.3 (±11.3) days for acute cerebral events, 
and 25.8 (±18.1) days for acute peripheral vascular 
events. These observations reinforce the belief that 
rebound hypercoagulability may occur following 
abrupt cessation of anticoagulant medication 
resulting in an increased cardiovascular risk of about 
11 events per 1000 patients per week (the background 
cardiovascular event rate being about 1.4/1000 
patients/week).16 Patients with coronary stents are at 
high risk of thromboembolic events and are usually 
prescribed dual anticoagulant therapy for the 
prevention of such events in future.  
 
In these patients, it has been observed that the 
greatest risk for stent thrombosis after implantation 
is premature discontinuation of clopidogrel. A 
systematic review examining the effects of short-
term discontinuation of anticoagulant therapy in 
patients with drug-eluting stents found that out of 
the 161 cases of late stent thrombosis (occurring ≥30 
days after insertion), 142 (88%) had stopped one or 
both of their anticoagulant medications 
perioperatively.17 In 33 patients who discontinued 
both anticoagulants simultaneously, the median 
time to event was 7 days (39% occurred within 5 
days of cessation). In 15 patients who stopped aspirin 
after having previously discontinued clopidogrel, the 
median time to event was also 7 days (27% occurred 
within 5 days). Moreover, in 94 patients who 
stopped clopidogrel but remained on aspirin, the 
median time to event was 122 days (2% within 5 
days). There were no events in patients who stopped 
aspirin but continued with clopidogrel.  
 
Risk of Bleeding Associated with Continuation 
of Anticoagulant Medications 
Patients taking oral anticoagulants have a prolonged 
bleeding time; however, this may not be clinically 
relevant. Clinically significant post-operative 
bleeding following dental procedures has been 
defined as bleeding that continues beyond 12 hours, 
causes the patient to return to the dental clinic or to 
an emergency department, results in the 
development of a large haematoma or ecchymosis 
within the oral soft tissues, or requires a blood 
transfusion.18 When compared with some other 
types of systemic surgical procedures, routine 
periodontal therapeutic procedures and minor 
dental surgeries carried out in the clinic setting, are 
less likely to be affected by prolonged bleeding 
time.19,20 Blood loss is usually minimal and has minor 
consequences for the patient even if prolonged. 
Furthermore, local hemostatic measures can be 
easily applied in the oral cavity. Thus, for most 
dental procedures, any increased risk of bleeding 
does not necessarily increase clinically significant 
adverse outcomes for the patient or affect the result 
of the procedure.1 In a randomized placebo-
controlled study involving 36 healthy patients 
receiving either aspirin 325 mg or placebo for two 
days prior to periodontal therapy like flap curettage 
and two days post treatment, no significant 
difference between aspirin and placebo was found 
with respect to intra-oral bleeding time (7.2 [±5.9] 
and 5.9 [±6.2] min, respectively; P=0.51) or the 
duration of bleeding following flap curettage (3.5 
[±2.9] and 5.2 [±6.3] hrs, respectively; P=0.31).21  
 
In another prospective study comprising 82 patients 
undergoing open flap debridement, the mean 
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bleeding time for those who stopped their regular  
low-dose aspirin before surgery (n=25) was not 
clinically or statistically significantly increased when 
compared with those who continued aspirin therapy 
without any interruption or alteration (n=32) and 
those who had never taken anticoagulant 
medication (3 min [±2 min 45 sec] vs. 2 min 45 sec [± 
1 min 38 sec] and 1 min 49 sec [± 39 sec], 
respectively).22 No patient experienced any episode 
of prolonged or significant bleeding post-surgery. In 
another study conducted on 39 patients undergoing 
dental extractions, none of the patients who 
continued with aspirin as prescribed (n=19) had a 
bleeding time outside normal range.23 Intraoperative 
bleeding was controlled in 85% of the patients 
(n=33) with gauze packing and proper suturing. The 
remaining 6 patients had tranexamic acid added to 
the gauze pack. No patient experienced 
uncontrolled bleeding in the immediate 
postoperative period or in the week following the 
procedure. In contrast to anticoagulant 
monotherapy, fewer studies are available on the 
bleeding risks of dual anticoagulant therapy. Reports 
suggest that the use of aspirin in combination with 
dipyridamole does not increase bleeding risk.24 In a 
retrospective cohort study involving 43 patients on 
single (n=14) or dual (n=29) anticoagulant therapy 
(aspirin+ clopidogrel, n=26; aspirin+dipyridamole, 
n=2; aspirin+ticlopidine, n=1) who had received at 
least one invasive dental procedure, no episodes of 
postoperative bleeding complications were observed 
in the 213 dental extractions (including 19 surgical 
extractions) performed.25 Although published 
studies on the relative risks of perioperative bleeding 
with clopidogrel or dipyridamole monotherapy are 
limited, the pharmacological mechanisms 
underlying their anticoagulant action suggest that 
patients taking these medications as monotherapy 
will be at no greater risk of bleeding than those 
taking aspirin. Therefore, patients on either 
clopidogrel or dipyridamole monotherapy should 
not have their therapy discontinued or altered prior 
to undertaking periodontal surgical procedures.26 
NSAIDs other than aspirin may also increase 
bleeding time; however, this seldom exceeds normal 
limits. Even major surgery is usually not complicated 
by these drugs, and therefore, they should not be 
discontinued prior to undertaking periodontal 
therapeutic procedures.27 
 
 
 
Weighing the Risk of Thromboembolic Events 
with that of Periprocedural Bleeding 
Risk of thromboembolic complications, including 
fatalities, associated with perioperative cessation of 
anticoagulant monotherapy is well documented. 
Although the risk is relatively low, the adverse 
outcome is potentially serious. On the contrary, not 
a single report exists of uncontrollable bleeding 
following dental or periodontal treatment 
undertaken without anticoagulant discontinuation. 
The meta analysis carried out by Burger and 
colleagues16 examining the cardiovascular risks 
associated with perioperative discontinuation of 
low-dose aspirin therapy prior to surgical procedures 
versus the bleeding risks associated with the 
continuation of therapy found that surgeons who 
were blinded to treatment failed to distinguish 
between patients taking aspirin and those 
discontinues it. In most cases, bleeding 
complications were handled in the same way as they 
would be without the effect of aspirin. The study 
also showed that discontinuation of aspirin resulted 
in serious adverse consequences such as stroke, 
myocardial infarction, and cardiovascular death. In 
the light of available evidence, guidance documents 
have been published advising that anticoagulant 
therapy should only be discontinued in the 
perioperative period when the haemorrhagic risk of 
continuing them is categorically higher than the 
cardiovascular risk associated with their 
discontinuation.5 Furthermore, since the premature 
interruption of clopidogrel or aspirin plus 
clopidogrel carries the risk of major adverse 
cardiovascular events that have devastating 
consequences, patients taking dual anticoagulant 
therapy should never have their anticoagulant 
regimen altered without the advice of an 
interventional cardiologist.1  
 
The American Dental Association, American Heart 
Association, American College of Cardiology, 
American College of Surgeons, and Society for 
Cardiovascular Angiography and Interventions have 
issued a joint advisory statement specifying the 
importance of preventing premature 
discontinuation of dual anticoagulant therapy in 
patients with coronary artery stents.[28] It states 
that there is little or no indication to interrupt 
anticoagulant drug regimen for dental procedures.  
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Managing the Risk of Bleeding in Patients  
Receiving Anticoagulant Therapy 
Dental procedures that can be undertaken in the 
clinic, including nonsurgical extraction of upto three 
teeth, surgical removal of teeth, gingivectomy, 
periodontal flap surgery, apicoectomy, scaling and 
root planing, etc., can be safely carried out without 
altering or interrupting anticoagulant medication.18 
Such patients should ideally be scheduled at the 
beginning of the day, preferably at the beginning of 
the week. Local anaesthetic containing a 
vasoconstrictor should ideally be used in these 
patients.18,29 Regional nerve blocks should be 
avoided wherever possible. In case of tooth 
extraction, the extraction sockets should be cleaned 
and gently packed with a resorbable hemostatic 
dressing, such as oxidised cellulose, collagen sponge, 
or resorbable gelatin sponge and carefully sutured.30 
Resorbable sutures are preferred as they attract less 
plaque accumulation.30 For the management of 
postoperative pain, paracetamol is a safe over-
thecounter analgesic in these patients and can be 
taken in normal doses for pain control. Additional 
options include dihydrocodeine. Other NSAIDs are 
considered less safe and should be avoided if 
possible. They may damage the gut lining leading to 
bleeding and ulceration, which may be further 
worsened by aspirin or clopidogrel administration. 
Some patients under anticoagulant medications may 
have additional medical problems, such as liver or 
renal impairment, thrombocytopenia, haemophilia, 
or other coagulation disorders, which might 
compound or increase the risk of prolonged 
bleeding after dental extractions and/or periodontal 
surgeries.1 Before treating these patients, the dentist 
must consult with the patient’s physician or 
haematologist to determine whether or not care can 
be safely delivered in the dental clinic.  
 
CONCLUSION  
Bleeding complications, while troublesome, do not 
carry the same risks as thromboembolic 
complications. Bleeding time in patients receiving 
anticoagulant medications is likely to be prolonged; 
however, perioperative or postoperative blood loss 
in these patients is usually minimal and should be 
manageable using local haemostatic measures only. 
These patients are placed at an increased risk of 
severe thromboembolic events with potentially 
serious consequences if their regular anticoagulant 
medications are discontinued. The recommendation 
therefore is that the anticoagulant drug regimen 
should never be stopped or altered prior to any 
dental surgical procedure, which includes 
periodontal surgical therapy as well as exodontia. 
 
Conflict Of Interest & Source of Funding 
The author declares that there is no source of 
funding and there is no conflict of interest among all 
authors.  
 
REFERENCES 
 1. Surgical management of the primary care dental 
patient on antiplatelet medication. North West 
Medicines Information Centre. Liverpool, UK. 
August 2010.  
2. Merritt JC, Bhatt DL. The efficacy and safety of 
perioperative antiplatelet therapy. J Thromb 
Thrombolysis 2002;13:97-103.  
3. Schafer AI. Effects of nonsteroidal 
antiinflammatory drugs on platelet function and 
systemic haemostasis. J Clin Pharmacol 1995;35:209-
19.  
4. Ferrari E, Benhamou M, Cerboni P, Marcel B. 
Coronary syndromes following aspirin withdrawal. A 
special risk for late stent thrombosis. J Am Coll 
Cardiol 2005;45:456-9.  
5. Samama CM, Bastien O, Forestier F, Denninger 
MH, Isetta c, Juliard JM, et al. French Society of 
Anaesthesiology and Intensive Care. Antiplatelet 
agents in perioperative period: expert 
recommendations of the French Society of 
Anaesthesiology and Intensive Care (SFAR) 2001-
summary statement. Can J Anaesth 2002;49:S26-35.  
6. Lecompte T, Hardy JF. Antiplatelet agents and 
perioperative bleeding. Can J Anaesth 2006;53:S103-
12.  
7. Cahill RA, McGreal GT, Crowe BH, Ryan DA, 
Manning BJ, Cahill MR, et al. Duration of increased 
bleeding tendency after cessation of aspirin therapy. 
J Am Coll Surg 2005;200:564-73. 
 8. Mielk CH Jr. Aspirin prolongation of the template 
bleeding time: Influence of venostasis and direction 
of incision. Blood 1982;60:1139-42.  
9. Douketis JD, Berger PB, Dunn AS, Jaffer AK, 
Spyropoulos AC, Becker RC, et al. American College 
of Chest Physicians. The perioperative management 
of antithrombotic therapy; America College of Chest 
Physicians Evidence-Based Clinical Practice 
Guidelines (8th edition). Chest 2008;133(6 
Suppl):299S-339S.  
10. Sandor G. Do patients taking oral anticoagulants 
need to discontinue their medication before surgical 
procedures? J Can Dental Assoc 2004;70:482-3.  
Perioperative Anticoagulant Discontinuation in Cardiovascular Patients                                                                        Vatsa R et al.            
210 
 International Healthcare Research Journal 2018;2(9):207-212.  
11. Nematullah A, Alabousi A, Blanas N, Douketis JD,  
Sutherland SE. Dental surgery for patients on 
anticoagulant therapy with warfarin: a systematic 
review and meta-analysis. J Can Dent Assoc 
2009;75:41a-i.  
12. Perry DJ, Noakes TJ, Helliwel PS. British Dental 
Society. Guidelines for the management of patients 
on oral anticoagulants requiring dental surgery. Br 
Dent J 2007;207:389-93.  
13. Baker RI, Coughlin PB, Gallus AS, Harper PL, 
Salem HH, Wood EM. Warfarin Reversal Consensus 
Group. Warfarin reversal: consensus guidelines, on 
behalf of the Australian Society of Thrombosis and 
Haemostasis. Med J Aust 2004;181:492-7.  
14. Collet JP, Montalescot G, Blanchet B, Tanguy ML, 
Golmard JL, Choussat R, et al. Impact of prior use or 
recent withdrawal of oral antiplatelet agents on 
acute coronary syndromes. Circulation 
2004;110:2361-7.  
15. Collet JP, Himbert D, Steg PG. Myocardial 
infarction after aspirin cessation in stable coronary 
artery disease patients. Int J Cardiol 2000;76:257-8.  
16. Burger W, Chemnitius JM, Kneissel GD, Rucker 
G. Low-dose aspirin for secondary cardiovascular 
prevention-cardiovascular risks after its 
perioperative withdrawal versus bleeding risks with 
its continuation-review and meta-analysis. J Intern 
Med 2005;257:399-414.  
17. Eisenberg MJ, Richard PR, Libersan D, Filion KB. 
Safety of short term discontinuation of antiplatelet 
therapy in patients with drug-eluting stents. 
Circulation 2009;119:1634-42.  
18. Lockhart PB, Gibson J, Pond SH, Leitch J. Dental 
management considerations for the patient with an 
acquired coagulopathy. Part 1: Coagulopathies from 
systemic disease. Br Dent J 2003;195:439- 45.  
19. Servin F. Low-dose aspirin and clopidogrel: how 
to act in patients scheduled for day surgery. Curr 
Opin Anaesthesiol 2007;20:531-34.  
20. Partridge CG, Campbell JH, Alvarado F. The 
effect of platelet-altering medications on bleeding 
from minor oral surgery procedures. J Oral 
Maxillofac Surg 2008;66:93-97.  
21. Brennan MT, Valerin MA, Noll JL, Napenas JJ, 
Kent ML, Fox PC, et al. Aspirin use and 
postoperative bleeding from dental extractions. J 
Dent Res 2008;87:740-44. 
 22. Krishnan B, Shenoy NA, Alexander M. Exodontia 
and antiplatelet therapy. J Oral Maxillofac Surg 
2008;66:2063-6.  
23. Ardekian L, Gasper R, Peled M, Brener B, Laufer 
D. Does low-dose aspirin therapy complicate oral 
surgical procedures? J Am Dent Assoc 2000;131:331-5.  
24. Persantin/Persantin Retard [summary of product 
characteristics]. Berkshire, UK: Boehringer 
Ingelheim Limited;2012.  
25. Napenas JJ, Hong CH, Brennan MT, Furney SL, 
Fox PC, Lockhart PB. The frequency of bleeding 
complications after invasive dental treatment in 
patients receiving single or dual antiplatelet therapy. 
JADA 2009;140:690-5.  
26. Joint Formulary Committee. British National 
Formulary. 59 ed. London, UK: Royal 
Pharmaceutical Society of Great Britain/British 
Medical Association; 2010:23.  
27. Schafer AI. Effects of non-steroidal 
antiinflammatory drugs on platelet function and 
systemic hemostasis. J Clin Pharmacol 1995;35:209-
19.  
28. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, 
Lockhart PB, Moliterno DJ, et al. American Heart 
Association; American Colege of Cardiology; Society 
for Cardiovascular Angiography and Interventions; 
American College of Surgeons; American Dental 
Association; American College of Physicians. 
Prevention of premature discontinuation of dual 
antiplatelet therapy in patients with patients with 
coronary artery stents: a science advisory from the 
American Heart Association, American College of 
Cardiology, Society for Cardiovascular Angiography 
and Interventions, American College of Surgeons, 
and American Dental Association, with 
representation from the American College of 
Physicians. Circulation 2007;115:813-8. 
29. Alexander RE. Eleven myths of dentoalveolar 
surgery. J Am Dent Assoc 1998;129:1271-9.  
30. Scully C, Wolff A. Oral surgery in patients on 
anticoagulant therapy. Oral Surg Oral Med Oral 
Pathol Oral Radiol Endod 2002;94:57-64. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Perioperative Anticoagulant Discontinuation in Cardiovascular Patients                                                                        Vatsa R et al.            
211 
 International Healthcare Research Journal 2018;2(9):207-212.  
 
 
  
   
 
 
 
 
AUTHOR AFFILIATIONS: 
1. MDS (Oral and Maxillofacial Surgery), Senior Resident, Department of Dentistry, Darbhanga Medical College and Hospital, Darbhanga 
2. MDS (Prosthodontics), Tutor, Patna Dental College and Hospital, Patna 
3.  
Source of support: Nil, Conflict of interest: None declared 
*Corresponding Author:  
Dr. Ritesh Vatsa 
Senior Resident 
Department of Dentistry 
Darbhanga Medical College and Hospital 
Darbhanga 
Cite this article as:  
Vatsa R, Priyadarshini P. Safety of Perioperative Anticoagulant Discontinuation 
in Cardiovascular Patients Undergoing Periodontal Therapy. Int Healthc Res J. 
2018;2(9):207-212. doi: 10.26440/ihrj.v2i9.178 
Perioperative Anticoagulant Discontinuation in Cardiovascular Patients                                                                        Vatsa R et al.            
For article enquiry/author contact details, e-mail at: editor.ihrj@gmail.com 
212 
